Literature DB >> 17237824

SMAC/Diablo mediates the proapoptotic function of PUMA by regulating PUMA-induced mitochondrial events.

J Yu1, P Wang, L Ming, M A Wood, L Zhang.   

Abstract

p53-upregulated modulator of apoptosis (PUMA) is a BH3-only Bcl-2 family protein and an essential mediator of DNA damage-induced apoptosis. PUMA is localized in the mitochondria and induces apoptosis through the mitochondrial pathway. However, the mechanisms of PUMA-induced apoptosis remain unclear. In this study, we found that second mitochondria-derived activator of caspase (SMAC)/Diablo, a mitochondrial apoptogenic protein, mediates the proapoptotic function of PUMA by regulating PUMA-induced mitochondrial events. SMAC is consistently released into the cytosol in colon cancer cells undergoing PUMA-induced apoptosis. In SMAC-deficient cells, execution of PUMA-induced apoptosis is abrogated, in company with decreases in caspase activation, cytosolic release of cytochrome c and collapse of mitochondrial membrane potential. Reconstituting SMAC expression restored these events in the SMAC-deficient cells. Furthermore, SMAC and agents that mimic the inhibitor of apoptosis proteins (IAPs) inhibition function of SMAC significantly sensitize cells to PUMA-induced apoptosis. These results demonstrate an important role of SMAC in executing DNA damage-induced and PUMA-mediated apoptosis and suggest that SMAC participates in a feedback amplification loop to promote cytochrome c release and other mitochondrial events in apoptosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17237824     DOI: 10.1038/sj.onc.1210196

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  54 in total

1.  Proapoptotic protein Smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101.

Authors:  Wenbin Hu; Fang Wang; Jingsheng Tang; Xinyu Liu; Zhu Yuan; Chunlai Nie; Yuquan Wei
Journal:  J Biol Chem       Date:  2011-11-03       Impact factor: 5.157

2.  Study on norcantharidin-induced apoptosis in SMMC-7721 cells through mitochondrial pathways.

Authors:  Xian-qian Li; Shi-he Shao; Gui-lian Fu; Xiao-hong Han; Hong Gao
Journal:  Chin J Integr Med       Date:  2010-09-25       Impact factor: 1.978

3.  PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice.

Authors:  Wei Qiu; Bin Wu; Xinwei Wang; Monica E Buchanan; Miguel D Regueiro; Douglas J Hartman; Robert E Schoen; Jian Yu; Lin Zhang
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

4.  PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01.

Authors:  Crissy Dudgeon; Peng Wang; Xiameng Sun; Rui Peng; Quanhong Sun; Jian Yu; Lin Zhang
Journal:  Mol Cancer Ther       Date:  2010-10-26       Impact factor: 6.261

5.  Experimental study on the inhibitory effect of sodium cantharidinate on human hepatoma HepG2 cells.

Authors:  Shi-Qi Wen; Quan Chen; Ming Hu
Journal:  Afr J Tradit Complement Altern Med       Date:  2013-11-02

Review 6.  Potential therapeutic benefits of strategies directed to mitochondria.

Authors:  Amadou K S Camara; Edward J Lesnefsky; David F Stowe
Journal:  Antioxid Redox Signal       Date:  2010-08-01       Impact factor: 8.401

7.  Crizotinib induces PUMA-dependent apoptosis in colon cancer cells.

Authors:  Xingnan Zheng; Kan He; Lin Zhang; Jian Yu
Journal:  Mol Cancer Ther       Date:  2013-02-20       Impact factor: 6.261

8.  Promotion of Caspase Activation by Caspase-9-mediated Feedback Amplification of Mitochondrial Damage.

Authors:  Alan D Guerrero; Ingo Schmitz; Min Chen; Jin Wang
Journal:  J Clin Cell Immunol       Date:  2012-08-09

9.  PUMA is directly activated by NF-kappaB and contributes to TNF-alpha-induced apoptosis.

Authors:  P Wang; W Qiu; C Dudgeon; H Liu; C Huang; G P Zambetti; J Yu; L Zhang
Journal:  Cell Death Differ       Date:  2009-05-15       Impact factor: 15.828

10.  Identification of thymidylate synthase as a potential therapeutic target for lung cancer.

Authors:  K Takezawa; I Okamoto; S Tsukioka; J Uchida; M Kiniwa; M Fukuoka; K Nakagawa
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.